Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF

Blood

Volumn 105, Issue 11, 2005, Pages 4463-4469

  Guba, Markus ^a   Yezhelyev, Maksim ^b   Eichhorn, Martin E ^b   Schmid, Gerald ^b   Ischenko, Ivan ^b   Papyan, Armine ^b   Graeb, Christian ^b   Seeliger, Hendrik ^b   Geissler, Edward K ^b   Jauch, Karl Walter ^b   Bruns, Christiane J ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN; THROMBOPLASTIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MALE; MICROSCOPY; MICROTHROMBUS; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR THROMBUS; UPREGULATION; WESTERN BLOTTING;

EID: 21144443076     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-09-3540     Document Type: Article

References (34)

1. Semeraro N, Colucci M. Tissue factor in health and disease. Thromb Haemost. 1997;78:759-764.
2. Nemerson Y. Tissue factor and hemostasis. Blood. 1988;71:1-8.
3. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol. 1989;134:1087-1097.
4. Shen BQ, Lee DY, Cortopassi KM, Damico LA, Zioncheck TF, Vascular endothelial growth factor KDR receptor signaling potentiates tumor necrosis factor-induced tissue factor expression in endothelial cells. J Biol Chem. 2001;276:5281-5286.
5. Morrissey JH. Tissue factor: a key molecule in hemostatic and nonhemostatic systems. Int J Hematol. 2004;79:103-108.
6. Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci U S A. 1992;89:11832-11836.
7. Zhang Y, Deng Y, Luther U, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest. 1994;94:1320-1327.
8. Carmeliet P, Mackman N, Moons L, et al. Role of tissue factor in embryonic blood vessel development. Nature. 1996;383:73-75.
9. Schmelzle T, Hall MN. TOR, a central controller of cell growth, Cell. 2000;103:253-262.
10. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene. 2000;19:6680-6686.
11. Guba M, Graeb C, Jauch KW, Geissler EK. Proand anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation. 2004;77:1777-1782.
12. Kahan BD. Sirolimus: a ten-year perspective. Transplant Proc. 2004;36:71-75.
13. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004; 4:335-348.
14. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8:128-135.
15. Trotter JF. Sirolimus in liver transplantation. Transplant Proc. 2003;35:S193-S200.
16. Fortin MC, Raymond MA, Madore F, et al. Increased risk of thrombotic microangiopathy in patients receiving a cyctosporin-sirolimus combination. Am J Transplant. 2004;4:946-952.
17. Paramesh AS, Grosskreutz C, Florman SS, et al. Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation. Transplantation. 2004;77:129-131.
18. Barone GW, Gurley BJ, Abul-Ezz SR, Gokden N. Sirolimus-induced thrombotic microangiopathy in a renal transplant recipient. Am J Kidney Dis. 2003;42:202-206.
19. Robson M, Cote I, Abbs I, Koffman G, Goldsmith D. Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage? Am J Transplant. 2003;3:324-327.
20. Choi SB. CYPHER coronary stents and risk of thrombosis. CMAJ. 2003;169:218.
21. Thorpe PE, Ran S. Tumor infarction by targeting tissue factor to tumor vasculature. Cancer J. 2000;6(suppl 3):S237-S244.
22. Bruns CJ, Koehl GE, Guba M, et al. Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin Cancer Res. 2004;10:2109-2119.
23. Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res. 2000;6:1936-1948.
24. Seeliger H, Guba M, Koehl GE, et al. Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy. Clin Cancer Res. 2004;10:1843-1852.
25. Manegold PC, Hutter J, Pahernik SA, Messmer K, Dellian M. Platelet-endothelial interaction in tumor angiogenesis and microcirculation. Blood. 2003;101:1970-1976.
26. Koehl G, Guba M, Seeliger H, et al. Rapamycin treatment at immunosuppressive doses affects tumor blood vessel circulation. Transplant Proc. 2003;35:2135-2136.
27. Haubitz M, Brunkhorst R. Influence of a novel rapamycin analog on SDZ RAD on endothelial tissue factor and adhesion molecule expression. Transplant Proc. 2002;34:1124-1126.
28. Pullen N, Thomas G. The modular phosphorylation and activation of p70s6k. FEBS Lett. 1997;410:78-82.
29. Weng QP, Kozlowski M, Belham C, Zhang A, Comb MH, Avruch J. Regulation of the p70 S6 kinase by phosphorylation in vivo. Analysis using site-specific anti-phosphopeptide antibodies. J Biol Chem. 1998;273:16621-16629.
30. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401-410.
31. Blum S, Issbruker K, Willuweit A, et al. An inhibitory role of the phosphatidylinositol 3-kinase-signaling pathway in vascular endothelial growth factor-induced tissue factor expression. J Biol Chem. 2001;276:33428-33434.
32. Kim I, Oh JL, Ryu YS, et al. Angiopoietin-1 negatively regulates expression and activity of tissue factor in endothelial cells. FASEB J. 2002;16:126-128.
33. Hu P, Van J, Sharifi J, Bai T, Khawli LA, Epstein AL. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Cancer Res. 2003;63:5046-5053.
34. Philipp J, Dienst A, Unruh M, et al. Soluble tissue factor induces coagulation on tumor endothelial cells in vivo if coadministered with low-dose lipopolysaccharides. Arterioscler Thromb Vasc Biol. 2003;23:905-910.